bioMerieux (OTCMKTS:BMXMF) Shares Up 5.6% – Here’s Why

bioMerieux (OTCMKTS:BMXMF) shares shot up 5.6% on Friday . The stock traded as high as $87.7980 and last traded at $87.7980. 125 shares were traded during mid-day trading, a decline of 67% from the average session volume of 374 shares. The stock had previously closed at $83.17.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler began coverage on shares of bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Zacks Research downgraded bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Morgan Stanley lowered bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

bioMerieux Price Performance

The firm’s 50-day moving average is $80.50 and its 200-day moving average is $92.67. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.